Phase 4 N=3,591 Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Covid19
Primary: 21 Day Organ Support (Respiratory or Vasopressor) Free Days — 22; 22; 17; 17 days — p=.6778
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Tenosynovial Giant Cell Tumor
Primary: Number of Treatment-Free Participants at 12 Months In The Treatment-free/Re-treatment Cohort — 8 Participants
Phase 4 N=444 Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Admission Rate — 98; 188 Participants
Phase 4 N=71 Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy
Constipation · Post-Op Complication
Primary: First Bowel Movement — 1.96; 2.32 days
Phase 4 N=9 Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging
Lymphedema
Primary: Time for Initial Disease Pattern to Appear — 5 seconds
Phase 4 N=59 A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device in Adult Participants for the Appearance of Cellulite
Cellulite
Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…
Phase 4 N=381 Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Chronic Obstructive Pulmonary Disease
Primary: FEV1 — 101; 78 mL — p=0.22
Phase 4 N=100 Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Advanced Non-Small Cell Lung Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 94; 89 Participants
Phase 4 N=68 Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
Mitochondrial Diseases
Primary: Difference in Mitochondrial Respiratory Function — 36; 32; -3 pmols/s/mg — p=0.6051
Phase 4 N=10 Brain and Stress Study
Stress, Psychological · Motivation
Primary: Change in Response Bias During the Probabilistic Reward Task — 0.195; 0.203 Ratio (Response Bias Score) — p=0.856
Phase 4 N=53 A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin Amyloid Cardiomyopathy
Primary: Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) — 45; 21; 17; 6 Participants
Phase 4 N=14 A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Gaucher Disease, Type 3
Primary: Percent Change From Baseline in Spleen Volume Measured by MRI — -51.33 Percent change
Phase 4 N=288 Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
Alcohol Use Disorder
Primary: Number of Participants With Continuous Sobriety According to Alcohol Timeline Follow Back — 66; 39 Participants
Phase 4 N=2,404 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction
Healthy
Primary: Number of Vaccines Administered by Participating Pharmacies in the Intervention and Non-intervention Communities Before and During the Intervention. — 3,093; 5,011…
Phase 4 N=19 DTA (Dopaminergic Therapy for Anhedonia) Study
Depression · Anhedonia
Primary: Targeted Ventral Striatum to Ventromedial Prefrontal Cortex (VS-vmPFC) Connectivity — 0.183; 0.219; 0.275; 0.202 Mean subject-level FC Z scores